Top

Published in:

01-09-2014 | CLINICAL

Antibody-based imaging strategies for cancer

Authors: Jason M. Warram, Esther de Boer, Anna G. Sorace, Thomas K. Chung, Hyunki Kim, Rick G. Pleijhuis, Gooitzen M. van Dam, Eben L. Rosenthal

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Abstract

Although mainly developed for preclinical research and therapeutic use, antibodies have high antigen specificity, which can be used as a courier to selectively deliver a diagnostic probe or therapeutic agent to cancer. It is generally accepted that the optimal antigen for imaging will depend on both the expression in the tumor relative to normal tissue and the homogeneity of expression throughout the tumor mass and between patients. For the purpose of diagnostic imaging, novel antibodies can be developed to target antigens for disease detection, or current FDA-approved antibodies can be repurposed with the covalent addition of an imaging probe. Reuse of therapeutic antibodies for diagnostic purposes reduces translational costs since the safety profile of the antibody is well defined and the agent is already available under conditions suitable for human use. In this review, we will explore a wide range of antibodies and imaging modalities that are being translated to the clinic for cancer identification and surgical treatment.

Sliwkowski, M. X., & Mellman, I. (2013). Antibody therapeutics in cancer. Science, 341(6151), 1192–1198. doi:10.1126/science.1241145341/6151/1192.PubMed

LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011). Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clinical Cancer Research, 17(20), 6437–6447. doi:10.1158/1078-0432.Ccr-11-0762.PubMed

Sampath, L., Kwon, S., Ke, S., Wang, W., Schiff, R., Mawad, M. E., et al. (2007). Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. Journal of Nuclear Medicine, 48(9), 1501–1510. doi:10.2967/jnumed.107.042234.PubMed

Peng, X. H., Qian, X. M., Mao, H., Wang, A. Y., Chen, Z., Nie, S. M., et al. (2008). Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. International Journal of Nanomedicine, 3(3), 311–321.PubMedCentralPubMed

van Dam, G. M., Themelis, G., Crane, L. M., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., et al. (2011). Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature Medicine, 17(10), 1315–1319. doi:10.1038/nm.2472nm.2472.PubMed

Korb, M. L., Hartman, Y. E., Kovar, J., Zinn, K. R., Bland, K. I., & Rosenthal, E. L. (2013). Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. Journal of Surgical Research. doi:10.1016/j.jss.2013.11.1089.

van Scheltinga, A. G. T. T., van Dam, G. M., Nagengast, W. B., Ntziachristos, V., Hollema, H., Herek, J. L., et al. (2011). Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. Journal of Nuclear Medicine, 52(11), 1778–1785. doi:10.2967/Jnumed.111.092833.

Byrne, W. L., DeLille, A., Kuo, C., de Jong, J. S., van Dam, G. M., Francis, K. P., et al. (2013). Use of optical imaging to progress novel therapeutics to the clinic. Journal of Controlled Release, 172(2), 523–534. doi:10.1016/j.jconrel.2013.05.004S0168-3659(13)00250-2.PubMed

van der Vorst, J. R., Schaafsma, B. E., Verbeek, F. P., Keereweer, S., Jansen, J. C., van der Velden, L. A., et al. (2013). Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncology, 49(1), 15–19. doi:10.1016/j.oraloncology.2012.07.017S1368-8375(12)00245-X.PubMedCentralPubMed

10.

Alberti, C. (2012). From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy. European Review for Medical and Pharmacological Sciences, 16(14), 1925–1933.PubMed

11.

Bai, M., & Bornhop, D. J. (2012). Recent advances in receptor-targeted fluorescent probes for in vivo cancer imaging. Current Medicinal Chemistry, 19(28), 4742–4758.PubMed

12.

Bremer, C., Ntziachristos, V., & Weissleder, R. (2003). Optical-based molecular imaging: contrast agents and potential medical applications. European Radiology, 13(2), 231–243. doi:10.1007/s00330-002-1610-0.PubMed

13.

Du, W., Wang, Y., Luo, Q. M., & Liu, B. F. (2006). Optical molecular imaging for systems biology: from molecule to organism. Analytical and Bioanalytical Chemistry, 386(3), 444–457. doi:10.1007/S00216-006-0541-Z.PubMedCentralPubMed

14.

Hoppin, J., Orcutt, K. D., Hesterman, J. Y., Silva, M. D., Cheng, D., Lackas, C., et al. (2011). Assessing antibody pharmacokinetics in mice with in vivo imaging. Journal of Pharmacology and Experimental Therapeutics, 337(2), 350–358. doi:10.1124/jpet.110.172916jpet.110.172916.PubMed

15.

Liu, Y., Yu, G., Tian, M., & Zhang, H. (2011). Optical probes and the applications in multimodality imaging. Contrast Media & Molecular Imaging, 6(4), 169–177. doi:10.1002/cmmi.428.

16.

Ntziachristos, V., Bremer, C., & Weissleder, R. (2003). Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. European Radiology, 13(1), 195–208. doi:10.1007/S00330-002-1524-X.PubMed

17.

Ripoll, J., Ntziachristos, V., Cannet, C., Babin, A. L., Kneuer, R., Gremlich, H. U., et al. (2008). Investigating pharmacology in vivo using magnetic resonance and optical imaging. Drugs in R&D, 9(5), 277–306. doi:10.2165/00126839-200809050-00001.

18.

Sokolov, K., Nida, D., Descour, M., Lacy, A., Levy, M., Hall, B., et al. (2007). Molecular optical imaging of therapeutic targets of cancer. Advances in Cancer Research, 96(96), 299–344. doi:10.1016/S0065-230x(06)96011-4.PubMed

19.

Schaafsma, B. E., van der Vorst, J. R., Gaarenstroom, K. N., Peters, A. A., Verbeek, F. P., de Kroon, C. D., et al. (2012). Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecologic Oncology, 127(1), 126–130. doi:10.1016/j.ygyno.2012.07.002S0090-8258(12)00496-9.PubMedCentralPubMed

20.

van der Vorst, J. R., Schaafsma, B. E., Verbeek, F. P., Hutteman, M., Mieog, J. S., Lowik, C. W., et al. (2012). Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Annals of Surgical Oncology, 19(13), 4104–4111. doi:10.1245/s10434-012-2466-4.PubMedCentralPubMed

21.

van der Vorst, J. R., Schaafsma, B. E., Verbeek, F. P., Swijnenburg, R. J., Hutteman, M., Liefers, G. J., et al. (2013). Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. British Journal of Dermatology, 168(1), 93–98. doi:10.1111/bjd.12059.PubMedCentralPubMed

22.

Verbeek, F. P., Troyan, S. L., Mieog, J. S., Liefers, G. J., Moffitt, L. A., Rosenberg, M., et al. (2014). Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Research and Treatment, 143(2), 333–342. doi:10.1007/s10549-013-2802-9.PubMed

23.

Beer, A. J., & Schwaiger, M. (2008). Imaging of integrin alphavbeta3 expression. Cancer and Metastasis Reviews, 27(4), 631–644. doi:10.1007/s10555-008-9158-3.PubMed

24.

Ye, Y., & Chen, X. (2011). Integrin targeting for tumor optical imaging. Theranostics, 1, 102–126.PubMedCentralPubMed

25.

Faust, A., Waschkau, B., Waldeck, J., Holtke, C., Breyholz, H. J., Wagner, S., et al. (2009). Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases. Bioconjugate Chemistry, 20(5), 904–912. doi:10.1021/bc8004478.PubMed

26.

Sheth, R. A., Kunin, A., Stangenberg, L., Sinnamon, M., Hung, K. E., Kucherlapati, R., et al. (2012). In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer. Molecular Imaging, 11(5), 417–425.PubMedCentralPubMed

27.

van Dongen, G. A., Visser, G. W., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007). Immuno-PET: a navigator in monoclonal antibody development and applications. The Oncologist, 12(12), 1379–1389. doi:10.1634/theoncologist.12-12-137912/12/1379.PubMed

28.

Kaur, S., Venktaraman, G., Jain, M., Senapati, S., Garg, P. K., & Batra, S. K. (2012). Recent trends in antibody-based oncologic imaging. Cancer Letters, 315(2), 97–111. doi:10.1016/j.canlet.2011.10.017S0304-3835(11)00634-3.PubMedCentralPubMed

29.

Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H. J. (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncology, 7(5), 392–401. doi:10.1016/s1470-2045(06)70665-9.PubMed

30.

Ishizawa, T., Fukushima, N., Shibahara, J., Masuda, K., Tamura, S., Aoki, T., et al. (2009). Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer, 115(11), 2491–2504. doi:10.1002/cncr.24291.PubMed

31.

Mieog, J. S., Hutteman, M., van der Vorst, J. R., Kuppen, P. J., Que, I., Dijkstra, J., et al. (2011). Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Research and Treatment, 128(3), 679–689. doi:10.1007/s10549-010-1130-6.PubMed

32.

Pleijhuis, R. G., Graafland, M., de Vries, J., Bart, J., de Jong, J. S., & van Dam, G. M. (2009). Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Annals of Surgical Oncology, 16(10), 2717–2730. doi:10.1245/s10434-009-0609-z.PubMedCentralPubMed

33.

Van Terwisscha Scheltinga, A. G. T., Van Dam, G. M., Nagengast, W. B., Ntziachristos, V., Hollema, H., Herek, J. L., et al. (2011). Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. Journal of Nuclear Medicine, 52(11), 1778–1785.

34.

Korb, M. L., Hartman, Y. E., Kovar, J., Zinn, K. R., Bland, K. I., & Rosenthal, E. L. (2014). Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. Journal of Surgical Research, 188(1), 119–128.PubMed

35.

Day, K. E., Sweeny, L., Kulbersh, B., Zinn, K. R., & Rosenthal, E. L. (2013). Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Molecular Imaging and Biology, 15(6), 722–729.PubMedCentralPubMed

36.

Heath, C. H., Deep, N. L., Sweeny, L., Zinn, K. R., & Rosenthal, E. L. (2012). Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Annals of Surgical Oncology, 19(12), 3879–3887. doi:10.1245/s10434-012-2435-y.PubMedCentralPubMed

37.

Wu, A. M. (2014). Engineered antibodies for molecular imaging of cancer. Methods, 65(1), 139–147. doi:10.1016/j.ymeth.2013.09.015S1046-2023(13)00384-8.PubMed

38.

Agdeppa, E. D., & Spilker, M. E. (2009). A review of imaging agent development. AAPS Journal, 11(2), 286–299. doi:10.1208/S12248-009-9104-5.PubMedCentralPubMed

39.

Scheuer, W., van Dam, G. M., Dobosz, M., Schwaiger, M., & Ntziachristos, V. (2012). Drug-based optical agents: infiltrating clinics at lower risk. Science Translational Medicine, 4(134), 134ps111. doi:10.1126/scitranslmed.30035724/134/134ps11.

40.

Lappin, G., Wagner, C. C., Langer, O., & van de Merbel, N. (2009). New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis, 1(2), 357–366. doi:10.4155/Bio.09.40.PubMed

41.

Pauwels, E. K. J., Bergstrom, K., Mariani, G., & Kairemo, K. (2009). Microdosing, imaging biomarkers and SPECT: a multi-sided tripod to accelerate drug development. Current Pharmaceutical Design, 15(9), 928–934.PubMed

42.

Wagner, C. C., & Langer, O. (2011). Approaches using molecular imaging technology—use of PET in clinical microdose studies. Advanced Drug Delivery Reviews, 63(7), 539–546. doi:10.1016/J.Addr.2010.09.011.PubMedCentralPubMed

43.

Ferrara, K., Pollard, R., & Borden, M. (2007). Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annual Review of Biomedical Engineering, 9, 415–447. doi:10.1146/annurev.bioeng.8.061505.095852.PubMed

44.

Klibanov, A. L. (1999). Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging. Advanced Drug Delivery Reviews, 37(1–3), 139–157.PubMed

45.

Bachmann, C., Klibanov, A. L., Olson, T. S., Sonnenschein, J. R., Rivera-Nieves, J., Cominelli, F., et al. (2006). Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn’s disease. Gastroenterology, 130(1), 8–16. doi:10.1053/j.gastro.2005.11.009.PubMed

46.

Ferrante, E. A., Pickard, J. E., Rychak, J., Klibanov, A., & Ley, K. (2009). Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. Journal of Controlled Release, 140(2), 100–107. doi:10.1016/j.jconrel.2009.08.001S0168-3659(09)00544-6.PubMedCentralPubMed

47.

Kaufmann, B. A., Sanders, J. M., Davis, C., Xie, A., Aldred, P., Sarembock, I. J., et al. (2007). Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation, 116(3), 276–284. doi:10.1161/CIRCULATIONAHA.106.684738.PubMed

48.

Lindner, J. R., Song, J., Christiansen, J., Klibanov, A. L., Xu, F., & Ley, K. (2001). Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation, 104(17), 2107–2112.PubMed

49.

Warram, J. M., Sorace, A. G., Saini, R., Umphrey, H. R., Zinn, K. R., & Hoyt, K. (2011). A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. Journal of Ultrasound in Medicine, 30(7), 921–931.PubMedCentralPubMed

50.

Willmann, J. K., Lutz, A. M., Paulmurugan, R., Patel, M. R., Chu, P., Rosenberg, J., et al. (2008). Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology, 248(3), 936–944. doi:10.1148/radiol.2483072231248/3/936.PubMedCentralPubMed

51.

Deshpande, N., Pysz, M. A., & Willmann, J. K. (2010). Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis, 13(2), 175–188. doi:10.1007/s10456-010-9175-z.PubMedCentralPubMed

52.

Kaufmann, B. A. (2009). Ultrasound molecular imaging of atherosclerosis. Cardiovascular Research, 83(4), 617–625. doi:10.1093/cvr/cvp179cvp179.PubMed

53.

Schumann, P. A., Christiansen, J. P., Quigley, R. M., McCreery, T. P., Sweitzer, R. H., Unger, E. C., et al. (2002). Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Investigative Radiology, 37(11), 587–593. doi:10.1097/01.RLI.0000031077.17751.B2.PubMed

54.

Sheffield, P., Trehan, A., Boyd, B., & Wong, O. L. (2008). Microbubbles as ultrasound contrast agents and in targeted drug delivery. Critical Reviews in Biomedical Engineering, 36(4), 225–255.PubMed

55.

Kiessling, F., Huppert, J., & Palmowski, M. (2009). Functional and molecular ultrasound imaging: concepts and contrast agents. Current Medicinal Chemistry, 16(5), 627–642.PubMed

56.

Saini, R., Warram, J. M., Sorace, A. G., Umphrey, H., Zinn, K. R., & Hoyt, K. (2011). Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents. Ultrasound in Medicine and Biology, 37(8), 1306–1313. doi:10.1016/j.ultrasmedbio.2011.05.010S0301-5629(11)00253-5.PubMedCentralPubMed

57.

Hoyt, K., Sorace, A., & Saini, R. (2012). Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model. Journal of Ultrasound in Medicine, 31(11), 1759–1766.PubMedCentralPubMed

58.

Sorace, A. G., Saini, R., Mahoney, M., & Hoyt, K. (2012). Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. Journal of Ultrasound in Medicine, 31(10), 1543–1550.PubMedCentralPubMed

59.

Korpanty, G., Carbon, J. G., Grayburn, P. A., Fleming, J. B., & Brekken, R. A. (2007). Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clinical Cancer Research, 13(1), 323–330. doi:10.1158/1078-0432.CCR-06-1313.PubMed

60.

Lyshchik, A., Fleischer, A. C., Huamani, J., Hallahan, D. E., Brissova, M., & Gore, J. C. (2007). Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. Journal of Ultrasound in Medicine, 26(11), 1575–1586.PubMedCentralPubMed

61.

Czarnota, G. J., Karshafian, R., Burns, P. N., Wong, S., Al Mahrouki, A., Lee, J. W., et al. (2012). Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 109(30), E2033–E2041. doi:10.1073/pnas.12000531091200053109.PubMedCentralPubMed

62.

Willmann, J. K., Paulmurugan, R., Chen, K., Gheysens, O., Rodriguez-Porcel, M., Lutz, A. M., et al. (2008). US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology, 246(2), 508–518. doi:10.1148/radiol.24620705362462070536.PubMed

63.

Warram, J. M., Sorace, A. G., Mahoney, M., Samuel, S., Harbin, B., Joshi, M., et al. (2014). Biodistribution of P-selectin targeted microbubbles. Journal of Drug Targeting. doi:10.3109/1061186X.2013.869822.PubMed

64.

65.

Knowles, J. A., Heath, C. H., Saini, R., Umphrey, H., Warram, J., Hoyt, K., et al. (2012). Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma. Archives of Otolaryngology - Head and Neck Surgery, 138(7), 662–668. doi:10.1001/archoto.2012.10811217425.PubMedCentralPubMed

66.

Warram, J. M., Sorace, A. G., Saini, R., Borovjagin, A. V., Hoyt, K., & Zinn, K. R. (2012). Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles. Cancer Gene Therapy, 19(8), 545–552. doi:10.1038/cgt.2012.29cgt201229.PubMedCentralPubMed

67.

Eisenbrey, J. R., Burstein, O. M., Kambhampati, R., Forsberg, F., Liu, J. B., & Wheatley, M. A. (2010). Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery. Journal of Controlled Release, 143(1), 38–44. doi:10.1016/j.jconrel.2009.12.021.PubMedCentralPubMed

68.

Sorace, A. G., Warram, J. M., Umphrey, H., & Hoyt, K. (2012). Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. Journal of Drug Targeting, 20(1), 43–54. doi:10.3109/1061186X.2011.622397.PubMedCentralPubMed

69.

Sorace, A. G., Saini, R., Rosenthal, E., Warram, J. M., Zinn, K. R., & Hoyt, K. (2013). Optical fluorescent imaging to monitor temporal effects of microbubble-mediated ultrasound therapy. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 60(2), 281–289. doi:10.1109/TUFFC.2013.2564.PubMedCentralPubMed

70.

Leong-Poi, H., Kuliszewski, M. A., Lekas, M., Sibbald, M., Teichert-Kuliszewska, K., Klibanov, A. L., et al. (2007). Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circulation Research, 101(3), 295–303. doi:10.1161/CIRCRESAHA.107.148676.PubMed

71.

Leong-Poi, H. (2012). Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications in progressive diabetic nephropathy. Seminars in Nephrology, 32(5), 494–504. doi:10.1016/j.semnephrol.2012.07.013S0270-9295(12)00137-4.PubMed

72.

Rapoport, N., Gao, Z., & Kennedy, A. (2007). Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. Journal of the National Cancer Institute, 99(14), 1095–1106. doi:10.1093/jnci/djm043.PubMed

73.

Phillips, L. C., Klibanov, A. L., Wamhoff, B. R., & Hossack, J. A. (2010). Targeted gene transfection from microbubbles into vascular smooth muscle cells using focused, ultrasound-mediated delivery. Ultrasound in Medicine and Biology, 36(9), 1470–1480. doi:10.1016/j.ultrasmedbio.2010.06.010.PubMedCentralPubMed

74.

Tsutsui, J. M., Xie, F., & Porter, R. T. (2004). The use of microbubbles to target drug delivery. Cardiovascular Ultrasound, 2, 23. doi:10.1186/1476-7120-2-23.PubMedCentralPubMed

75.

Weinmann, H. J., Brasch, R. C., Press, W. R., & Wesbey, G. E. (1984). Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR. American Journal of Roentgenology, 142(3), 619–624. doi:10.2214/ajr.142.3.619.PubMed

76.

Curtet, C., Bourgoin, C., Bohy, J., Saccavini, J. C., Thedrez, P., Akoka, S., et al. (1988). Gd-25 DTPA-MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: preliminary studies. International Journal of Cancer. Supplement = Journal International du Cancer. Supplement, 2, 126–132.PubMed

77.

Shahbazi-Gahrouei, D. (2009). Novel MR imaging contrast agents for cancer detection. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 14(3), 141–147.

78.

Sun, B. (1994). [Comparative studies of 111In-labeled monoclonal antibody using spacer-containing and non-spacer bifunctional chelates: (II). Biodistribution, metabolism and excretion in vivo]. [Research Support, Non-U.S. Gov’t]. Kaku igaku. The Japanese Journal of Nuclear Medicine, 31(5), 473–487.

79.

Kuriu, Y., Otsuji, E., Kin, S., Nakase, Y., Fukuda, K., Okamoto, K., et al. (2006). Monoclonal antibody conjugated to gadolinium as a contrast agent for magnetic resonance imaging of human rectal carcinoma. Journal of Surgical Oncology, 94(2), 144–148. doi:10.1002/jso.20411.PubMed

80.

Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews, 53(2), 283–318.PubMed

81.

Kohler, N., Sun, C., Fichtenholtz, A., Gunn, J., Fang, C., & Zhang, M. (2006). Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Small, 2(6), 785–792. doi:10.1002/smll.200600009.PubMed

82.

Lacava, L. M., Lacava, Z. G., Da Silva, M. F., Silva, O., Chaves, S. B., Azevedo, R. B., et al. (2001). Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. [Research Support, Non-U.S. Gov’t]. Biophysical Journal, 80(5), 2483–2486. doi:10.1016/S0006-3495(01)76217-0.PubMedCentralPubMed

83.

Quaglia, F., Ostacolo, L., De Rosa, G., La Rotonda, M. I., Ammendola, M., Nese, G., et al. (2006). Nanoscopic core-shell drug carriers made of amphiphilic triblock and star-diblock copolymers. [Research Support, Non-U.S. Gov’t]. International Journal of Pharmaceutics, 324(1), 56–66. doi:10.1016/j.ijpharm.2006.07.020.PubMed

84.

Hadjipanayis, C. G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A. J., Chen, H., et al. (2010). EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Cancer Research, 70(15), 6303–6312. doi:10.1158/0008-5472.CAN-10-1022.PubMedCentralPubMed

85.

Wei, X., Tang, H., Shang, Y. W., Li, G. H., Li, A., Wang, L., et al. (2013). [Cytotoxicity of PFOB nanoparticle coupled with ICAM-1 antibody on cardiomyocytes and its targeted adhesion to injured cardiomyocytes in vitro]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical Science Edition, 44(3), 342–347.PubMed

86.

Boswell, C. A., & Brechbiel, M. W. (2007). Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nuclear Medicine and Biology, 34(7), 757–778. doi:10.1016/j.nucmedbio.2007.04.001.PubMedCentralPubMed

87.

Tolmachev, V., & Stone-Elander, S. (2010). Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochimica et Biophysica Acta, 1800(5), 487–510. doi:10.1016/j.bbagen.2010.02.002S0304-4165(10)00050-4.PubMed

88.

Perk, L. R., Vosjan, M. J., Visser, G. W., Budde, M., Jurek, P., Kiefer, G. E., et al. (2010). p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 37(2), 250–259. doi:10.1007/s00259-009-1263-1.PubMedCentralPubMed

89.

Zeglis, B. M., Sevak, K. K., Reiner, T., Mohindra, P., Carlin, S. D., Zanzonico, P., et al. (2013). A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. Journal of Nuclear Medicine, 54(8), 1389–1396. doi:10.2967/jnumed.112.115840jnumed.112.115840.PubMed

90.

Borjesson, P. K., Jauw, Y. W., Boellaard, R., de Bree, R., Comans, E. F., Roos, J. C., et al. (2006). Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clinical Cancer Research, 12(7 Pt 1), 2133–2140. doi:10.1158/1078-0432.CCR-05-2137.PubMed

91.

Borjesson, P. K., Jauw, Y. W., de Bree, R., Roos, J. C., Castelijns, J. A., Leemans, C. R., et al. (2009). Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. Journal of Nuclear Medicine, 50(11), 1828–1836. doi:10.2967/jnumed.109.065862jnumed.109.065862.PubMed

92.

Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., et al. (2010). Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics, 87(5), 586–592. doi:10.1038/clpt.2010.12clpt201012.PubMed

93.

Divgi, C. R., Pandit-Taskar, N., Jungbluth, A. A., Reuter, V. E., Gonen, M., Ruan, S., et al. (2007). Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncology, 8(4), 304–310. doi:10.1016/S1470-2045(07)70044-X.PubMed

94.

Tinianow, J. N., Gill, H. S., Ogasawara, A., Flores, J. E., Vanderbilt, A. N., Luis, E., et al. (2010). Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nuclear Medicine and Biology, 37(3), 289–297. doi:10.1016/j.nucmedbio.2009.11.010S0969-8051(09)00291-1.PubMed

95.

Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., et al. (2010). Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chemistry Review, 110(5), 2795–2838. doi:10.1021/cr900300p.

96.

Plaetzer, K., Krammer, B., Berlanda, J., Berr, F., & Kiesslich, T. (2009). Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers in Medical Science, 24(2), 259–268. doi:10.1007/s10103-008-0539-1.PubMed

97.

Fingar, V. H., Wieman, T. J., & Haydon, P. S. (1997). The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochemistry and Photobiology, 66(4), 513–517.PubMed

98.

Fingar, V. H., Wieman, T. J., Karavolos, P. S., Doak, K. W., Ouellet, R., & Vanlier, J. E. (1993). The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochemistry and Photobiology, 58(2), 251–258. doi:10.1111/J.1751-1097.1993.Tb09557.X.PubMed

99.

McMahon, K. S., Wieman, T. J., Moore, P. H., & Fingar, V. H. (1994). Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Research, 54(20), 5374–5379.PubMed

100.

Krosl, G., Korbelik, M., & Dougherty, G. J. (1995). Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. British Journal of Cancer, 71(3), 549–555.PubMedCentralPubMed

101.

Biel, M. A. (1998). Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope, 108(9), 1259–1268.PubMed

102.

Fan, K. F. M., Hopper, C., Speight, P. M., Buonaccorsi, G., MacRobert, A. J., & Bown, S. G. (1996). Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer, 78(7), 1374–1383.PubMed

103.

Gluckman, J. L. (1991). Hematoporphyrin photodynamic therapy—is there truly a future in head and neck oncology—reflections on a 5-year experience. Laryngoscope, 101(1), 36–42.PubMed

104.

Grosjean, P., Savary, J. F., Mizeret, J., Wagnieres, G., Woodtli, A., Theumann, J. F., et al. (1996). Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. Journal of Clinical Laser Medicine and Surgery, 14(5), 281–287.PubMed

105.

Grossweiner, L. I., Hill, J. H., & Lobraico, R. V. (1987). Photodynamic therapy of head and neck squamous cell carcinoma: optical dosimetry and clinical trial. Photochemistry and Photobiology, 46(5), 911–917.PubMed

106.

Keller, G. S., Doiron, D. R., & Fisher, G. U. (1985). Photodynamic therapy in otolaryngology–head and neck surgery. Archives of Otolaryngology, 111(11), 758–761.PubMed

107.

Savary, J. F., Monnier, P., Fontolliet, C., Mizeret, J., Wagnieres, G., Braichotte, D., et al. (1997). Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Archives of Otolaryngology - Head and Neck Surgery, 123(2), 162–168.PubMed

108.

Taber, S. W., Fingar, V. H., & Wieman, T. J. (1998). Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. Journal of Surgical Oncology, 68(4), 209–214. doi:10.1002/(SICI)1096-9098(199808)68:4<209::AID-JSO2>3.0.CO;2-8.PubMed

109.

Wyss, P., Schwarz, V., Dobler-Girdziunaite, D., Hornung, R., Walt, H., Degen, A., et al. (2001). Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. International Journal of Cancer, 93(5), 720–724. doi:10.1002/Ijc.1400.

110.

Baas, P., Saarnak, A. E., Oppelaar, H., Neering, H., & Stewart, F. A. (2001). Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. British Journal of Dermatology, 145(1), 75–78. doi:10.1046/J.1365-2133.2001.04284.X.PubMed

111.

Jeffes, E. W., McCullough, J. L., Weinstein, G. D., Fergin, P. E., Nelson, J. S., Shull, T. F., et al. (1997). Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid—a pilot dose-ranging study. Archives of Dermatology, 133(6), 727–732. doi:10.1001/Archderm.133.6.727.PubMed

112.

McCaughan, J. S., Jr., Guy, J. T., Hicks, W., Laufman, L., Nims, T. A., & Walker, J. (1989). Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Archives of Surgery, 124(2), 211–216.PubMed

113.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013S0092-8674(11)00127-9.PubMed

114.

Duska, L. R., Hamblin, M. R., Bamberg, M. P., & Hasan, T. (1997). Biodistribution of charged F(ab’)(2) photoimmunoconjugates in a xenograft model of ovarian cancer. British Journal of Cancer, 75(6), 837–844. doi:10.1038/Bjc.1997.149.PubMedCentralPubMed

115.

Pelegrin, A., Folli, S., Buchegger, F., Mach, J. P., Wagnieres, G., & van den Bergh, H. (1991). Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer, 67(10), 2529–2537.PubMed

116.

Slinkin, M. A., Curtet, C., Faivrechauvet, A., Saimaurel, C., Gestin, J. F., Torchilin, V. P., et al. (1993). Biodistribution of anti-Cea F(Ab’)2 fragments conjugated with chelating polymers—influence of conjugate electron charge on tumor uptake and blood clearance. Nuclear Medicine and Biology, 20(4), 443–452. doi:10.1016/0969-8051(93)90075-6.PubMed

117.

Vrouenraets, M. B., Visser, G. W., Stewart, F. A., Stigter, M., Oppelaar, H., Postmus, P. E., et al. (1999). Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Research, 59(7), 1505–1513.PubMed

118.

Vrouenraets, M. B., Visser, G. W. M., Loup, C., Meunier, B., Stigter, M., Oppelaar, H., et al. (2000). Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: a new possibility for use in photodynamic therapy. International Journal of Cancer, 88(1), 108–114. doi:10.1002/1097-0215(20001001)88:1<108::Aid-Ijc17>3.0.Co;2-H.

119.

Brasseur, N., Langlois, R., La Madeleine, C., Ouellet, R., & van Lier, J. E. (1999). Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Photochemistry and Photobiology, 69(3), 345–352. doi:10.1562/0031-8655(1999)069<0345:Rmtopt>2.3.Co;2.PubMed

120.

Del Governatore, M., Hamblin, M. R., Piccinini, E. E., Ugolini, G., & Hasan, T. (2000). Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin(e6) immunoconjugates. British Journal of Cancer, 82(1), 56–64.PubMedCentralPubMed

121.

Mew, D., Wat, C. K., Towers, G. H., & Levy, J. G. (1983). Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. Journal of Immunology, 130(3), 1473–1477.

122.

Pogrebniak, H. W., Matthews, W., Black, C., Russo, A., Mitchell, J. B., Smith, P., et al. (1993). Targeted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surgical Oncology, 2(1), 31–42.PubMed

123.

Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L., & Kobayashi, H. (2011). Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature Medicine, 17(12), 1685–1691. doi:10.1038/nm.2554nm.2554.PubMedCentralPubMed

124.

Detty, M. R., Gibson, S. L., & Wagner, S. J. (2004). Current clinical and preclinical photosensitizers for use in photodynamic therapy. Journal of Medicinal Chemistry, 47(16), 3897–3915. doi:10.1021/Jm040074b.PubMed

125.

Ntziachristos, V., Ripoll, J., Wang, L. H. V., & Weissleder, R. (2005). Looking and listening to light: the evolution of whole-body photonic imaging. Nature Biotechnology, 23(3), 313–320. doi:10.1038/Nbt1074.PubMed

126.

Nakajima, T., Sano, K., Mitsunaga, M., Choyke, P. L., & Kobayashi, H. (2012). Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging. Cancer Research, 72(18), 4622–4628. doi:10.1158/0008-5472.CAN-12-12980008-5472.CAN-12-1298.PubMedCentralPubMed

127.

Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005). Monoclonal antibody successes in the clinic. Nature Biotechnology, 23(9), 1073–1078. doi:10.1038/nbt0905-1073.PubMed

128.

Waldmann, T. A. (2003). Immunotherapy: past, present and future. Nature Medicine, 9(3), 269–277. doi:10.1038/nm0303-269nm0303-269.PubMed

129.

Nakajima, T., Sano, K., Choyke, P. L., & Kobayashi, H. (2013). Improving the efficacy of photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics, 3(6), 357–365. doi:10.7150/thno.5908thnov03p0357.PubMedCentralPubMed

Title: Antibody-based imaging strategies for cancer
Authors: Jason M. Warram
Esther de Boer
Anna G. Sorace
Thomas K. Chung
Hyunki Kim
Rick G. Pleijhuis
Gooitzen M. van Dam
Eben L. Rosenthal
Publication date: 01-09-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9505-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2014

Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases

Novel drugs targeting the androgen receptor pathway in prostate cancer

Circulating tumour cells—a bona fide cause of metastatic cancer

A multi-targeted approach to treating bone metastases

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer